• Mashup Score: 2

    The risk of early recurrence in medically treated patients with intracranial atherosclerotic stenosis (ICAS) may differ in clinical trials versus real-world settings. Delayed enrollment may contribute to lower event rates in ICAS trials. We aim to determine the 30-day recurrence risk in a real-world setting of symptomatic ICAS.

    Tweet Tweets with this article
    • In patients with symptomatic #ICAD, the real-world recurrent #stroke is ~20% & >>>> than that seen in clinical trials (~4%) even in subgroups receiving the same pharmacological treatment strategies. Read our most recent on this! https://t.co/wFd7Xtdido @EricGoldsteinMD @ShuLiqi

  • Mashup Score: 1

    © American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is qualified 501(c)(3) tax-exempt organization.*Red Dress ™ DHHS, Go Red ™; AHA; National Wear Red Day ® is registered trademark.

    Tweet Tweets with this article
    • #STROKE Highlights by @NicoleBSur: Outcomes in #cancer patients receiving reperfusion, predictors of early infarct recurrence in #ICAD, and adolescent #obesity and stroke in the young https://t.co/WaCbn2M9Gr https://t.co/XVjs8C7EXa